Note 1 - Organization and Description of Business

12 Months Ended

Dec. 31, 2020

Notes to Financial Statements

Nature of Operations [Text Block]

1.

Organization and Description of Business

Diffusion Pharmaceuticals Inc., a Delaware corporation, an innovative biopharmaceutical company developing novel therapies that enhance the body's ability to deliver oxygen to the areas where it is needed most. The Company's lead product candidate, TSC, is being developed to enhance the diffusion of oxygen to tissues with low oxygen levels, also known as hypoxia, a serious complication of many of medicine's most intractable and difficult-to-treat conditions.

In addition to TSC, the Company's product candidate DFN-

529,

a novel, allosteric

PI3K/Akt/mTOR

pathway inhibitor, is in early-stage development. The Company previously completed

two

Phase

1

clinical trials evaluating DFN-

529

in age-related macular degeneration. DFN-

529

was also previously in preclinical development in oncology, specifically GBM.